Article
Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity.
All News
Dr. Antoni Chan
Tweet
Younger age, male gender, geographic region, lower weight and BMI, dactylitis+ or enthesitis+, lower scores Pt-Pain, PtGA, TJC and HAQ-DI were baseline predictors for achieving MDA and DAPSA LDA at Week 56 in UPA treated patients @RheumNow #ACR21 Abst#1348 https://t.co/FSXarBoBM1 https://t.co/UMCjr6eCRm
Eric Dein
Tweet
#ACR21 Ab#1029 - Great poster by Dr. Guttmann, IRAD in Summit NJ:
▶️2019 EULAR/ACR SLE criteria vs to 1997 ACR & SLICC
⭐️64% SLE pts: all 3 criteria. 10% only SLICC, 3% '97 ACR, 2% EULAR/ACR
⭐️Simliar gender, racial disparities to prior criteria
@Rheumnow https://t.co/QzG78HJgw5 https://t.co/eyuYhj4Acf
Mrinalini Dey
Tweet
Almost like real-life, I've "run across the conference centre" to catch the end of the #InterstitialLungDisease session- some excellent insights from Dr Melissa Griffith on a complex topic, will definitely be reviewing the full talk later.
#ACR21 @RheumNow https://t.co/LdhXI8LLqY
Eric Dein
Tweet
#ACR21 Abst#1029 @Rheumnow https://t.co/QzG78HJgw5
What is your preferred SLE classification criteria?
Janet Pope
Tweet
#ILD in #rheumatic diseases. When to use #glucocorticoids and immune suppressive sand anti fibrotic. V clear but harder in real world! @RheumNow #ACR21 #ACRBest https://t.co/R4V5ZggRsu
David Liew
Tweet
Steroids can cause co-morbidities which increase CV risk, but can PNL directly increase CV event (MACE) risk in RA?
30d PNL➡️15% increase in MACE in next 30d
(independent of underlying CV risk, RA dx activity)
PNL actively confers risk!
@BethIWallace #ACR21 ABST1428 @RheumNow https://t.co/cuL69n7cx3
Eric Dein
Tweet
#ACR21 Abs:#1429: ALPN-303: Dual BAFF/APRIL antagonist for SLE:
⭐️Encouraging immunomodulatory activity and efficacy in animal models. ⬇️ Plasma cells and Ig secretions in vitro & vivo
⭐️Well-tolerated in animals w/o adverse events
🔥Phase 1 study in healthy volunteers!
@Rheumnow
Dr. Antoni Chan
Tweet
Physical exercise did not increase BME disease in SIJ and spine in PsA. The risk of increased BME after 11 weeks of HIIT was not higher compared to controls in a cohort of PsA patients with low to moderate disease activity @RheumNow #ACR21 Abst#1362 https://t.co/DHj4D5Ojb1 https://t.co/J4KV5zdpey
Olga Petryna
Tweet
Abst1424 #ACR2021 @RheumNow study of SEC in children w/ERA or JPsA : 72% reduced flare risk. Improved JADAS-27 score in both the ERA and JPsA categories. ⬇️ disease activity, enthesitis count & joints with active arthritis. adverse events & serious AEs in the SEC & PBO comparable https://t.co/J4MdxeYxWZ
Mrinalini Dey
Tweet
What predicts response to MTX in RA?
👉🏼DAS28-ESR
👉🏼RA duration
👉🏼Pt global assessment
👉🏼Swollen joint count
Abs#1227 #ACR21 @RheumNow
https://t.co/s942zvFiZ1
Mrinalini Dey
Tweet
Plenary Abs#1428 #ACR21
👉🏼Long-term #steroid use is common in RA incl in pts with high risk of #MACE
👉🏼30days of steroids ➡️ 15% increased odds of MACE
@RheumNow
https://t.co/fCM3m04ruS https://t.co/FWGmAatYu5
Bella Mehta
Tweet
26K Veterans data with RA #ACR21 plenary abst#1428
30 days on glucocorticoids - ⬆️15% odds of Major Adverse Cardiovascular events @RheumNow @BethIWallace https://t.co/BOram4o2rp
Aurelie Najm
Tweet
Role of GC on MACE in RA:
US database analysis 26000+pts
23% on GC >90d/6mo
Each 30days of GC dispensed ⏭15% increase in odds of MACE in the following 6month period!
Adjustment on several confounders but not disease activity.
#Abts1428 #ACR21 @RheumNow https://t.co/prdA7D5fLz https://t.co/F3wCcRAfuf
Mrinalini Dey
Tweet
Plenary Abs#1427 #ACR21
👉🏼#Statins assoc w/ reduced #CVD & all-cause mortality, outweighing
modest #T2DM risk increase in RA pts
👉🏼Reduction in all-cause mortality greater in RA than gen population
👉🏼Incr in T2DM risk is NOT greater in RA compared to gen population
@RheumNow https://t.co/WcF11B0C2s
Bella Mehta
Tweet
Statins in RA - plenary at #ACR21 UK Clinical
Practice Research Datalink 1989-2018 @RheumNow
Reduction in CVD risk, All cause mortality
INCREASE in Type 2 DM risk🧐 - need to make sure we look into it for RA patients!
Great work @UNMC_Rheum by Gulsen Ozen! https://t.co/YmTO0xcdjj
Aurelie Najm
Tweet
RA and CVD: take your statins!
Obs UK study
Statins ⬇️CVD HR=0.46
⬇️All cause death HR=0.68
w/ mild ⬆️ T2DM risk HR=1.33
(but not more than in general population)
⭐️NNT to prevent CVD 102
⭐️NNT to prevent death 46
⭐️NNH 127
#ACR21 #Abst1427 @RheumNow https://t.co/v6TinuklNv https://t.co/r0rD4jMmuh
Robert B Chao, MD
Tweet
PsO pts not on biologics had a ⬆️ risk of PsA compared to those on biologics
⭐️HR 1.39
⭐️retrospective cohort study w/ >1300 cases
Abs#1355
#ACR21
#ACRBest
@RheumNow
https://t.co/tL37we3lwc https://t.co/SAexvn9HMb
Dr. Antoni Chan
Tweet
In PsA patients with low baseline CRP treated with IXE or ADA, a favorable reduction in pain was observed for IXE-treated
patients, irrespective of controlled or non-controlled inflammation, as
measured by CRP or SJC improvement @RheumNow #ACR21 Abst#1341 https://t.co/Nl78oASmf5 https://t.co/2qSXQr2sQS
TheDaoIndex
Tweet
To statin or not to statin?
UK cohort study 22,000 RA pts eval CV risk/diabetes w/statins
Statins:⬇️CV events by 32%, ⬆️DM-2 by 33%, ⬇️all cause mortality by 54%
NNT 102➡️prevent CV events
NNT 42➡️prevent all cause mortality
NNH 127➡️cause DM-2
absr#1427 #plenary @rheumnow https://t.co/QAt6Ie4qa7
